Haleon plc Reports Share Transaction
Ticker: HLNCF · Form: 6-K · Filed: Sep 23, 2025 · CIK: 1900304
Sentiment: neutral
Topics: share-transaction, sec-filing, 6-K
Related Tickers: HLN
TL;DR
Haleon bought back some of its own stock on Sept 23, 2025.
AI Summary
Haleon plc announced on September 23, 2025, that it conducted a transaction in its own shares. The filing, a Form 6-K, details this activity as part of its reporting requirements for foreign private issuers. No specific financial figures or share counts were provided in this particular filing.
Why It Matters
This filing indicates ongoing corporate actions by Haleon plc, which can influence investor perception and stock performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share transactions and does not contain significant new financial or operational information.
Key Players & Entities
- Haleon plc (company) — Registrant
- 23 September 2025 (date) — Date of transaction
FAQ
What type of transaction did Haleon plc conduct in its own shares?
Haleon plc conducted a transaction in its own shares on September 23, 2025.
What form was filed with the SEC regarding this transaction?
Haleon plc filed a Form 6-K, which is a Report of Foreign Private Issuer.
What is the Commission File Number for Haleon plc?
The Commission File Number for Haleon plc is 001-41411.
What is the principal executive office address for Haleon plc?
The principal executive office address for Haleon plc is Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY.
Does Haleon plc file annual reports under Form 20-F or Form 40-F?
Haleon plc files annual reports under Form 20-F.
Filing Stats: 584 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-09-23 06:08:55
Filing Documents
- a3331a.htm (6-K) — 34KB
- a3331a000.jpg (GRAPHIC) — 3KB
- 0001654954-25-011007.txt ( ) — 40KB
From the Filing
IN OWN SHARES a3331a UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1 23 September 2025 - “Transaction in Own Shares”     99.1       Haleon plc:   Transaction in own shares   23 September 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 5,150,000 ordinary shares of £0.01 each in the Company (the "Shares")   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 22 September 2025 22 September 2025 22 September 2025 Number of Shares purchased: 3,507,000 1,000,000 643,000 Highest price paid per Share (p): 336.6000 334.0000 336.4000 Lowest price paid per Share (p): 332.7000 332.6000 332.7000 Volume weighted average price paid per Share (p): 333.9574 333.6379 333.9485   The Company intends to hold the purchased shares as treasury shares.   Following the settlement of the above, the Company's registered share capital   is 8,952,353,648 ordinary shares of £0.01 each, of which 28,187,545 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,924,166,103 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/3321A_1-2025-9-22.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zoë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .              SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 23, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary